Get the Stockscreener App
336.23
4.22%
-14.80
After Hours:
336.23
Madrigal Pharmaceuticals Inc stock is traded at $336.23, with a volume of 251.38K.
It is down -4.22% in the last 24 hours and up +9.49% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$351.03
Open:
$355
24h Volume:
251.38K
Relative Volume:
0.68
Market Cap:
$7.33B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-13.38
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-0.29%
1M Performance:
+9.49%
6M Performance:
+31.25%
1Y Performance:
+47.31%
1-Day Range:
$336.23
$355.00
1-Week Range:
$334.13
$355.00
52-Week Range:
$189.00
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
336.23 | 7.33B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals to Present at 45th Annual TD Cowen Health Care Conference - MyChesCo
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - The Manila Times
Can Madrigal's TD Cowen Conference Reveal Signal Major Clinical Progress? - StockTitan
Madrigal Pharmaceuticals (MDGL) to Release Quarterly Earnings on Wednesday - MarketBeat
Is Madrigal Pharmaceuticals (NASDAQ:MDGL) Using Debt Sensibly? - Simply Wall St
Kornitzer Capital Management Inc. KS Invests $4.55 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra sales fuel stock's growth potential - Investing.com Nigeria
Madrigal Pharmaceuticals Reports Q2 2024 Financial Results and Provides Updates - MSN
(MDGL) Investment Report - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Fiera Capital Corp - MarketBeat
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MSN
What is Leerink Partnrs' Estimate for MDGL FY2024 Earnings? - MarketBeat
Newbridge Financial Services Group Inc. Takes $1.30 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on - EIN News
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Rheos Capital Works Inc. Cuts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - The Motley Fool
Madrigal Pharmaceuticals CEO sells shares worth $531,020 - MSN
(01/29/25) Top Picks 2025: Madrigal Pharmaceuticals (MDGL) - Moneyshow.com
Madrigal Pharmaceuticals CEO sells shares worth $531,020 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals executive sells shares worth $34,529 - MSN
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells 1,584 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 103 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals executive sells shares worth $34,529 By Investing.com - Investing.com Canada
(MDGL) Trading Advice - Stock Traders Daily
Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Brokers Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
Cantor Fitzgerald Estimates MDGL FY2025 Earnings - Defense World
MDGL (Madrigal Pharmaceuticals) Long-Term Debt & Capital Le - GuruFocus.com
Cantor Fitzgerald Predicts MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making - TipRanks
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):